Latest news with #HPM
New Paper
06-05-2025
- New Paper
SMRT Trains fined $240,000 over accident that killed technical officer
Rail operator SMRT Trains was fined $240,000 on May 5 over an accident at Bishan Depot in March 2020 that killed one of its technical officers. The company was convicted of an offence under the Workplace Safety and Health Act, as it had failed to take reasonable measures to ensure its employees' safety at the depot in Bishan Road. On March 23, 2020, Mr Muhammad Afiq Senawi, 30, and a colleague were using a hydraulic press machine (HPM) to replace some train-related components. Mr Afiq had placed a component into the machine, and activated the piston to carry out the task. However, he had failed to remove a similar older component. Due to a pressure build-up, a spacer rod that weighed nearly 3kg flew out of the machine, broke through the fencing gate near the machine, and struck his face. Mr Afiq was rushed to Tan Tock Seng Hospital, where he died of face and chest injuries at 10.15am that day. Coroner Christopher Goh later ruled his death to be an unfortunate misadventure. Among other things, an investigation later revealed that SMRT Trains had failed to install a pressure gauge for the HPM after dismantling it for repairs. On May 5, Ministry of Manpower prosecutor Kimberly Boo told the court that the spacer rod had not been secured to any other component, adding: "There was thus a hazard of the spacer rod displacing from its position and shooting out during operations." She also said that a maintenance work record dated June 11, 2018, stated that the hydraulic pressure gauge was damaged. As a result, there was no indication of the pressure of the HPM available when it was in operation. The damage was reported to an engineering maintenance manager, who instructed for the gauge to be dismantled. However, he later overlooked its reinstallation. Another work record dated Dec 16 that year stated that the pressure gauge was sent for calibration. Court documents stated that the most recent maintenance of the HPM prior to the tragedy was carried out on Jan 2, 2020. The gauge was still not installed then. Ms Boo said: "(SMRT Trains) had failed to ensure that a pressure gauge, which was a safety measure identified in the HPM operation manual, was installed for the HPM. Once the activating lever was pulled by the operator, the piston would continually move downwards to generate a downward push motion. "Even though HPM operators were not required to monitor the exact pressure involved in the operation, the presence of a pressure gauge would provide an indication to operators on whether the force applied in any installation or removal had increased disproportionately." SMRT Trains had also failed to limit the pressure setting of the HPM, which would reduce operators' exposure to a force far beyond what was necessary for its intended use, thus lowering the risks of harm the operators are exposed to. SMRT Trains was charged in court in 2023.
AsiaOne
06-05-2025
- AsiaOne
SMRT Trains fined $240,000 over accident that killed technical officer, Singapore News
SINGAPORE – Rail operator SMRT Trains was fined $240,000 on May 5 over an accident at Bishan Depot in March 2020 that killed one of its technical officers. The company was convicted of an offence under the Workplace Safety and Health Act, as it had failed to take reasonable measures to ensure its employees' safety at the depot in Bishan Road. On March 23, 2020, Mr Muhammad Afiq Senawi, 30, and a colleague were using a hydraulic press machine (HPM) to replace some train-related components. Mr Afiq had placed a component into the machine, and activated the piston to carry out the task. However, he had failed to remove a similar older component. Due to a pressure build-up, a spacer rod that weighed nearly 3kg flew out of the machine, broke through the fencing gate near the machine, and struck his face. Mr Afiq was rushed to Tan Tock Seng Hospital, where he died of face and chest injuries at 10.15am that day. Coroner Christopher Goh later ruled his death to be an unfortunate misadventure. Among other things, an investigation later revealed that SMRT Trains had failed to install a pressure gauge for the HPM after dismantling it for repairs. On May 5, Ministry of Manpower prosecutor Kimberly Boo told the court that the spacer rod had not been secured to any other component, adding: 'There was thus a hazard of the spacer rod displacing from its position and shooting out during operations.' She also said that a maintenance work record dated June 11, 2018, stated that the hydraulic pressure gauge was damaged. As a result, there was no indication of the pressure of the HPM available when it was in operation. The damage was reported to an engineering maintenance manager, who instructed for the gauge to be dismantled. However, he later overlooked its reinstallation. Another work record dated Dec 16 that year stated that the pressure gauge was sent for calibration. Court documents stated that the most recent maintenance of the HPM prior to the tragedy was carried out on Jan 2, 2020. The gauge was still not installed then. Ms Boo said: '(SMRT Trains) had failed to ensure that a pressure gauge, which was a safety measure identified in the HPM operation manual, was installed for the HPM. Once the activating lever was pulled by the operator, the piston would continually move downwards to generate a downward push motion. 'Even though HPM operators were not required to monitor the exact pressure involved in the operation, the presence of a pressure gauge would provide an indication to operators on whether the force applied in any installation or removal had increased disproportionately.' SMRT Trains had also failed to limit the pressure setting of the HPM, which would reduce operators' exposure to a force far beyond what was necessary for its intended use, thus lowering the risks of harm the operators are exposed to. SMRT Trains was charged in court in 2023. [[nid:481768]] This article was first published in The Straits Times. Permission required for reproduction.
Straits Times
05-05-2025
- Straits Times
SMRT Trains fined $240,000 over accident that killed technical officer
SMRT technical officer Muhammad Afiq Senawi was killed after rod weighing nearly 3kg hit his face in 2020. PHOTO: ST FILE SINGAPORE – Rail operator SMRT Trains was fined $240,000 on May 5 over an accident at Bishan Depot in March 2020 that killed one of its technical officers. The company was convicted of an offence under the Workplace Safety and Health Act, as it had failed to take reasonable measures to ensure its employees' safety at the depot in Bishan Road. On March 23, 2020, Mr Muhammad Afiq Senawi, 30, and a colleague were using a hydraulic press machine (HPM) to replace some train-related components. Mr Afiq had placed a component into the machine, and activated the piston to carry out the task. However, he had failed to remove a similar older component. Due to a pressure build-up, a spacer rod that weighed nearly 3kg flew out of the machine, broke through the fencing gate near the machine, and struck his face. Mr Afiq was rushed to Tan Tock Seng Hospital, where he died of face and chest injuries at around 10.15am that day. Coroner Christopher Goh later ruled his death to be an unfortunate misadventure. Among other things, an investigation later revealed that SMRT Trains had failed to install a pressure gauge for the HPM after dismantling it for repairs. On May 5, Ministry of Manpower prosecutor Kimberly Boo told the court that the spacer rod had not been secured to any other component, adding: 'There was thus a hazard of the spacer rod displacing from its position and shooting out during operations.' She also said that a maintenance work record dated June 11, 2018, stated that the hydraulic pressure gauge was damaged. As a result, there was no indication of the pressure of the HPM available when it was in operation. The damage was reported to an engineering maintenance manager, who instructed for the gauge to be dismantled. However, he later overlooked its reinstallation. Another work record dated Dec 16 that year stated that the pressure gauge was sent for calibration. Court documents stated that the most recent maintenance of the HPM prior to the tragedy was carried out on Jan 2, 2020. The gauge was still not installed then. Ms Boo said: '(SMRT Trains) had failed to ensure that a pressure gauge, which was a safety measure identified in the HPM operation manual, was installed for the HPM. Once the activating lever was pulled by the operator, the piston would continually move downwards to generate a downward push motion. 'Even though HPM operators were not required to monitor the exact pressure involved in the operation, the presence of a pressure gauge would provide an indication to operators on whether the force applied in any installation or removal had increased disproportionately.' SMRT Trains had also failed to limit the pressure setting of the HPM, which would reduce operators' exposure to a force far beyond what was necessary for its intended use, thus lowering the risks of harm the operators are exposed to. SMRT Trains was charged in court in 2023. Shaffiq Alkhatib is The Straits Times' court correspondent, covering mainly criminal cases heard at the State Courts. Join ST's WhatsApp Channel and get the latest news and must-reads.
Yahoo
01-05-2025
- Business
- Yahoo
HPM Oahu Design Center makes grand opening in Honolulu
HONOLULU (KHON2) — A new design center is opening soon in Honolulu and hopes to offer a one-stop destination for everything from home renovations to new builds. WakeUp2Day's Chris Latronic went live in Iwilei at Na Lama Kukui for an exclusive preview. Camp Agape Hawaii is ready to inspire for summer Na Lama Kukui invites the public to the unveiling of HPM's newest exceptional Design Centers on O'ahu. For over a century, HPM has been Hawai'i's premier building partner, and now they're bringing their legacy of excellence and innovation to Honolulu with a sophisticated, immersive design experience. Step into their trio of meticulously crafted showrooms where luxury meets functionality: Suite 104: Experience our signature collection of premium cabinetry, countertops and HPM Home package solutions Suite 108: Discover state-of-the-art appliances including Thermador, Bosch, and Gaggenau, as well as Bellmont, SmartCucina and Medallion cabinet lines. Suite 109: Explore an exquisite selection of finishes, fixtures, Ernestomeda cabinets, Miele appliances and a variety of upscale design elements that elevate island living Download the free KHON2 app for iOS or Android to stay informed on the latest news And if you visit all three showrooms and complete your event passport, you have the chance to win a $25,000 Thermador kitchen package. The package includes a Thermador refrigerator, induction range hood, dishwasher and undercounter wine unit. Savor an exceptional pupu menu by Prime Roast Cafe's Chef Ernesto and Celeste, featuring dishes like Garlic Infused Kona Lobster, Parker Ranch Prime Rib Bites and Big Island Vanilla Bean Panna Cotta. Pupu and refreshments will be served throughout the event in all three showrooms. Food is limited and on a first-come-first-serve basis. Witness culinary artistry with Chef Shayne Castellano's live demonstration using premium Thermador appliances and indulge in free samples from noon to 12:30 p.m. in Suite 108. Check out more news from around Hawaii And if you're part of the first 100 guests, you can receive an exclusive swag bag designed in partnership with celebrated local artist and Hilo native Kailah Ogawa. For more information, click HERE. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
22-04-2025
- Business
- Yahoo
CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape
DALLAS, TX / / April 22, 2025 / Mangoceuticals Inc. (NASDAQ:MGRX) is on a mission to rewrite the playbook for men's performance, health, and vitality. Its pursuit comes at a time when opportunities have become enormous, with patent expirations on several of the world's most popular health and wellness drugs, opening vast pathways to exploit segmented market opportunities, each worth billions. To get a deeper understanding of how Mangoceuticals Inc. intends to capture its share of these substantial revenue-generating opportunities, Hawk Point Media sat down with Jacob Cohen, CEO of Mangoceuticals, to discuss his brand's explosive rise, his vision for redefining men's health, and how MangoRx and PeachesRx are carving out a distinct and disruptive lane in a space crowded with copycats and outdated solutions. From ED and testosterone therapy to weight loss and hair restoration, Cohen offers a candid look at the science, strategy, and soul behind the company's bold mission. Here's what he said: HPM: Jacob, you have several products. But, one in particular has been earning a substantial amount of attention- Mango. Why and what makes it different from traditional ED products? JC: The "why" is simple. Mango isn't just a pill- it's a revolution in men's wellness. What makes Mango different is that it combines a unique blend of L-Arginine, Oxytocin, and either Sildenafil or Tadalafil-the main ingredients found in Viagra and Cialis. That combination, put into a fast-acting dissolvable tablet, delivers performance with science-backed innovation. Our goal at Mangoceuticals was to enhance the experience, as that component contributes significantly to overall wellness. That outcome is what drives the brand's growth. And so is the fact that, unlike traditional blue pills that come with a stigma, slow onset, and awkward pharmacy pickups, Mango taps into a new wave of user confidence and control. We've created two distinct versions of Mango to meet men wherever they are. Sildenafil Mango, with the tagline "Orange is the New Blue ," brings the quick-acting reliability that men have trusted for years-just faster and more fun. Tadalafil Mango, branded under "Make Every Day Hump Day" , offers a longer-lasting experience, designed for those who prefer flexibility throughout the day or weekend. Both versions are delivered to our customers in discreet packaging and are deliciously flavored to eliminate the clinical feel of old-school ED meds. With Mango, performance enhancement becomes part of your lifestyle, not a last-minute fix. HPM: Let's talk about ED - how big of a problem is it, and what's MangoRx doing about it? JC: It's a huge issue, and we intend to open the doors wider to available solutions. Varying statistics show that approximately 70% of men will face some form of erectile dysfunction during their lifetime. It's not just a condition for older guys or those with underlying health issues. Stress, lifestyle, psychological factors, and even overwork can play a role. ED has become a silent epidemic, impacting relationships, mental health, and confidence. Yet, for something so common, it remains shrouded in shame and misinformation. At MangoRx, we believe treating ED should be as normal as taking a multivitamin. That's why we've taken the science seriously and removed the stigma from the equation. Whether one prefers the fast, targeted effects of Sildenafil Mango or the sustained benefits of Tadalafil Mango, each formula is designed to meet men's needs with medical integrity and maximum convenience. There's no more running to the pharmacy or hiding a bottle in your drawer. Mango is available online, discreetly shipped, and tastes good - because we believe better performance starts with better experiences. HPM: You've introduced something called Prime by MangoRx. What is that, and how is it changing testosterone therapy? JC: Prime by MangoRx is where innovation meets transformation in testosterone replacement therapy (TRT). Again, we've changed the rules. Historically, TRT has been a painful and inconvenient process, involving injections, messy gels, and time-consuming doctor visits. But for the millions of men silently suffering from low testosterone-fatigue, low libido, mood swings, and weight gain, TRT is critical to restoring balance and vitality. With Prime, we're rewriting that experience. At the heart of the Prime protocol is Kyzatrex™, an FDA-approved oral testosterone capsule taken daily. It's a game-changer, offering safe and sustained testosterone levels without the dangerous hormonal spikes that traditional injections often cause. Even better, Prime is fully telehealth-enabled, meaning your blood kits arrive at your door, your appointments happen online with board-certified physicians, and your meds are shipped discreetly - no clinics, no waiting rooms, and no more painful intramuscular injections. This approach isn't just more convenient; it's also more effective, and patient compliance is often significantly greater. Prime is about optimizing men's hormones to support long-term energy, libido, muscle tone, and overall mood-without compromising comfort or safety. We believe that this protocol enables men, perhaps for the first time, to take control of their hormone health in a way that suits their lifestyle, rather than those of millions assigned to a segmented demographic. HPM: Let's switch gears. A lot of men are quietly struggling with hair loss. What makes Grow by MangoRx different from all the products out there? JC: You are right-many men do struggle with feelings about hair loss. Hair loss can be one of the most personal and frustrating changes men face, yet so many so-called treatments either overpromise or underdeliver. Shampoos, sprays, and subscription services flood the market, but few offer more than surface-level solutions. Grow by MangoRx was built to address the root causes-literally. Grow by MangoRx is a chewable, mint-flavored tablet formulated with clinical precision. It combines Minoxidil, a circulation booster that reactivates dormant follicles; Finasteride, which blocks the DHT hormone that interrupts healthy growth; Biotin, to fuel keratin production for stronger, shinier strands; and Vitamin D3, which helps strengthen the hair from within. In other words, while some products utilize one of the above or occasionally combine two, Grow by MangoRx is a comprehensive approach designed for daily use. Because it combines all the best ingredients to enable the best outcomes without leaving any greasy residues, we expect its market penetration to follow a similar growth trajectory to Mango. HPM: Another product in your portfolio, which uses the popular compound, Semaglutide, targets the booming weight-loss market. How does Slim by MangoRx change the game? JC: It is no secret that the weight-loss market is booming, with Semaglutide taking the weight-loss world by storm. And for good reason - it's effective. Semaglutide mimics a natural hormone in the body that regulates hunger, leading to real, sustained weight loss. But the standard delivery method - weekly injections - is a huge turn-off for a lot of people. Between the discomfort, preparation time, and cost, it is simply not a sustainable solution for many people. Remember, patient compliance is a mandatory hurdle to clear in any treatment. To achieve this, we developed Slim by MangoRx, a daily oral dissolving tablet that delivers the same powerful compound, Semaglutide, combined with Vitamin B6 for added metabolic support. It's mint-flavored, painless, and dissolves in seconds under the tongue. More importantly, it's effective as various studies have been performed validate Semaglutide's role in safe and consistent weight loss for those who struggle with obesity or excess weight. Slim by MangoRx also integrates our telehealth model to provide expert care and an easy-to-use solution delivered to a user's door. This is the solution for men who want to slim down without slowing down - the best part: no needles, no office visits, no pressure. HPM: That's not your only weight-loss product. Mangoceuticals announced an exclusive distribution agreement for Diabetinol®. How does this product fit into Mangoceuticals' broader vision, and does it take from Slim's market opportunities? JC: Not at all because it's a different product that we think serves a significantly underserved market. Diabetinol® can be a game-changing addition to our portfolio, and highlights the evolution of Mangoceuticals into a total wellness brand. Like our other portfolio products, this one supports our belief that clinically supported, effective treatments should be accessible, discreet, and empowering. Our telemedicine platform already provides innovative solutions for issues like ED, testosterone imbalance, hair loss, and weight management, but with Diabetinol®, we're stepping into an even bigger arena: metabolic health. This isn't just another supplement. It's a patented, plant-based nutraceutical derived from citrus peel and rich in polymethoxylated flavones, such as nobiletin and tangeretin, which have been shown in clinical trials to improve insulin sensitivity, suppress glucose production in the liver, and activate key enzymes that help the body manage fat more effectively. What excites me most is how Diabetinol offers a meaningful option to millions of people who struggle to manage their blood sugar or weight but cannot afford, tolerate, or gain access to GLP-1 medications like semaglutide. We're not positioning this as a direct substitute, but the science is incredibly compelling, especially for those who need a natural, affordable, and non-invasive tool to support their metabolic health journey. With this exclusive U.S. and Canadian license, we have secured a front-row seat in the $33 billion diabetes and metabolic wellness market, marking a major strategic leap forward for us. As importantly, it aligns perfectly with our mission to democratize access to impactful health solutions and ensure that no one is left behind simply because of cost or complexity. HPM: Mangoceuticals Inc. offers quite a range of treatments - ED, testosterone, hair, and weight loss. What's the bigger picture here? JC: The bigger picture is that we're not just building a men's health company - we're building a movement redefining how people engage with their bodies, their confidence, and their health goals. In other words, we're different than competitors who market the same prior generation of treatments and compounds with a different name. We have developed and brought to the market a new generation of treatments intended to deliver better outcomes. Here's better news-as we recently announced, MangoRx is now just one-half of that mission. The other half? PeachesRx, our sister brand, is dedicated exclusively to women's wellness. Like MangoRx, Peaches is built on the same belief and mission that healthcare should be empowering, personalized, and frictionless. PeachesRx delivers clinically backed solutions for women's sexual health, hormone balance, weight loss, and more, all with the same dedication to discretion, flavor-forward delivery formats, and telehealth ease. Together, MangoRx and PeachesRx form a comprehensive wellness ecosystem that recognizes that men and women deserve easy access to modern, stigma-free care. That model is an especially important value driver in today's connected world. We've been clear about our mission-Mangoceuticals is not in the business of selling pills. We're in the business of upgrading lives. HPM: That's an excellent mission. Do you have any final thoughts you would like to share with this audience? JC: At the end of the day, we're proving that performance, vitality, and self-care aren't niche luxuries available for the few-they're fundamental interests in how millions want to show up in the world. Whether it's with Mango, Prime, Grow, Slim, or the innovations from PeachesRx, we're helping people rewrite the rules of aging, energy, intimacy, and wellness. And I'll leave you with this: we're just getting started. End interview Published with permission from Hawk Point Media Group, Llc. About Mangoceuticals, Inc. is focused on developing a variety of men's and women's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management for men under the brands "MangoRx" and weight management products for women under the brand "PeachesRx". Interested consumers can use MangoRx's or PeachesRx's telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx's and/or PeachesRx's partner compounding pharmacy and right to the patient's doorstep. To learn more about MangoRx's mission and other products, please visit To learn more about PeachesRx, please visit Cautionary Note Regarding Forward-Looking StatementsCertain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, relating to, among other things: statements about the ability of our trials to demonstrate safety and efficacy of our product candidates, and other positive results; the risk that initial drug results are not predictive of future results or will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; the Company's reliance on third parties to conduct its clinical trials; unexpected adverse side effects or inadequate therapeutic efficacy of drug candidates that could limit approval and/or commercialization, or that could result in recalls or product liability claims; uncertainty of commercial success; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; including the risk that final results could differ from interim data released; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; the progress of our clinical trials; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care and other of our products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment; the investigation into, outcome of the investigation regarding, and potential lawsuits, claims and actions regarding, a potential stock manipulation scheme relating to the Company's common stock following the Company's prior reverse stock split; the outcome of certain outstanding legal matters, claims and allegations, the requirement that the Company spend cash and management's resources on such matters, even if the Company ultimately prevails in such matters, risks associated with certain counterparties to lawsuits having significantly greater resources than us, settlements we may choose to enter into in the future and the terms thereof, and potential regulatory reviews, inquiries or lawsuits, which are brought about by claims made in private lawsuits; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; our ability to meet the continued listing requirements of Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our products which have not been, and will not be, approved by the U.S. Food and Drug Administration (" FDA ") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (" FFDCA Act ") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; claims, lawsuits and litigation relating to our intellectual property, including allegations that our intellectual property infringes on the intellectual property of others, costs related to any such claims or lawsuits and resources required to expend in connection therewith; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions and risks associated with related party relationships and agreements; the projected size of the potential market for our technologies and products; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our products; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company's products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties. More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024. These filings are available at and at our website at All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Follow MangoRx on social media: FOR INVESTOR RELATIONSMangoceuticals Investor RelationsEmail: investors@ SOURCE: Mangoceuticals Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
